Medication Monitor

Generic Name (Trade Name—Company)
January 1, 2011


Diabetes is new indication for old drug


Treatment of type 2 diabetes as an adjunct to diet and exercise as monotherapy or in combination with other oral antidiabetic agents

The exact mechanism by which bromocriptine improves glycemic control is unknown; it may normalize aberrant hypothalamic neurotransmitter activities that induce, potentiate, and maintain the insulin-resistant, glucose-intolerant state. Data from four double-blind, placebo-controlled trials (one monotherapy and three add-on trials) involving more than 3,700 patients with type 2 diabetes showed that bromocriptine produced clinically significant improvements in glycosylated hemoglobin (A1C) (difference from placebo [range –0.4% to –0.6%]) and postprandial glucose, and more patients given bromocriptine reached an A1C goal of 7% or less compared with placebo. The recommended dose is 1.6–4.8 mg once daily. The tablets are currently available in pharmacies in a 0.8-mg strength.